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Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment a b s t r a c t
Risk assessment methodologies in toxicology have remained largely unchanged for decades. The default approach uses high dose animal studies, together with human exposure estimates, and conservative assessment (uncertainty) factors or linear extrapolations to determine whether a specific chemical exposure is 'safe' or 'unsafe'. Although some incremental changes have appeared over the years, results from all new approaches are still judged against this process of extrapolating high-dose effects in animals to low-dose exposures in humans. The US National Research Council blueprint for change, entitled Toxicity Testing in the 21st Century: A Vision and Strategy called for a transformation of toxicity testing from a system based on high-dose studies in laboratory animals to one founded primarily on in vitro methods that evaluate changes in normal cellular signalling pathways using human-relevant cells or tissues.
More recently, this concept of pathways-based approaches to risk assessment has been expanded by the description of 'Adverse Outcome Pathways' (AOPs). The question, however, has been how to translate this AOP/TT21C vision into the practical tools that will be useful to those expected to make safety decisions. We have sought to provide a practical example of how the TT21C vision can be implemented to facilitate a safety assessment for a commercial chemical without the use of animal testing. To this end, the key elements of the TT21C vision have been broken down to a set of actions that can be brought together to achieve such a safety assessment. Such components of a pathways-based risk assessment have been widely discussed, however to-date, no worked examples of the entire risk assessment process exist. In order to begin to test the process, we have taken the approach of examining a prototype toxicity pathway (DNA damage responses mediated by the p53 network) and constructing a strategy for the development of a pathway based risk assessment for a specific chemical in a case study mode. This contribution represents a 'work-in-progress' and is meant to both highlight concepts that are welldeveloped and identify aspects of the overall process which require additional development. To guide our understanding of what a pathways-based risk assessment could look like in practice, we chose to work on a case study chemical (quercetin) with a defined human exposure and to bring a multidisciplinary team of chemists, biologists, modellers and risk assessors to work together towards a safety assessment. Our goal was to see if the in vitro dose response for quercetin could be sufficiently understood to construct a TT21C risk assessment without recourse to rodent carcinogenicity study data. The data presented include high throughput pathway biomarkers (p-H2AX, p-ATM, p-ATR, p-Chk2, p53, p-p53, MDM2 and Wip1) and markers of cell-cycle, apoptosis and micronuclei formation, plus gene transcription in HT1080 cells. Eighteen point dose response curves were generated using flow cytometry and imaging to determine the concentrations that resulted in significant perturbation. NOELs and BMDs were compared to the output from biokinetic modelling and the potential for in vitro to in vivo extrapolation explored. A first tier risk assessment was performed comparing the total quercetin concentration in the in vitro systems with the
Introduction
The process of toxicological risk assessment is of paramount importance to society. It protects specific populations such as workers exposed to chemicals in an occupational setting, patients receiving pharmaceutical treatments, and whole populations exposed to chemicals in foods, consumer products and the environment. It is therefore critical that toxicological risk assessments take advantage of the best available scientific approaches. Current risk assessment methodologies have remained largely unchanged for decades. The default approach uses high dose animal studies, together with human exposure estimates, and conservative assessment (uncertainty) factors or linear extrapolations to determine whether a specific chemical exposure is 'safe' or 'unsafe'. Although some incremental changes appeared over the years, results from all new approaches are still judged against this process of extrapolating high-dose effects in animals to low-dose exposures in humans.
In 2007, the US National Research Council published a milestone blueprint for change, entitled Toxicity Testing in the 21st Century: A Vision and Strategy (NRC, 2007; Krewski et al., 2010) . The essence of this report was a call to transform toxicity testing from a system based on high-dose studies in laboratory animals to one founded primarily on in vitro methods that evaluate changes in normal cellular signalling pathways using human-relevant cells or tissues. The term 'toxicity pathway' was applied to a normal signalling process, which if significantly perturbed, would result in an adverse cellular outcome. More recently, this concept of pathways-based approaches to risk assessment has been expanded by the description of 'Adverse Outcome Pathways' (AOPs). Each AOP begins with a Molecular Initiating Event (MIE) in which the chemical interacts with a biological target, leading to a sequence of events across different levels of biological organization (subcellular, cellular, suborgan, organ, individual and population) and resulting in an adverse outcome with direct relevance to a given risk assessment context (Ankley et al., 2010) . Toxicity pathways find a home in the sequential description of steps leading from the MIE to the adverse outcome. The OECD have recently used this universal framework based on AOPs to capture and peer review the mechanistic understanding of specific toxic effects and provide a framework for the evaluation of non-animal methods that aim to predict key events in these pathways (OECD, 2011) . The question, however, has been how to translate this AOP/TT21C vision into the practical tools that will be useful to those expected to make safety decisions.
We have sought to provide a practical example of how the TT21C vision can be implemented to facilitate a safety assessment for a commercial chemical without the use of animal testing. To this end, the key elements of the TT21C vision have been broken down to a set of actions that can be brought together to achieve such a safety assessment in the context of assuring consumer safety for the use of novel ingredients within fast moving consumer goods (Fig. 1) . The process begins, as with traditional approaches for a new ingredient/chemical, with initial estimates of exposure and potential pathway activity. This includes consideration of the use of the ingredient within the product type -what are the expected human/consumer exposure scenarios (Hall et al., , 2011 and are the levels significant? These data may be used in combination with information on chemical structure (QSAR), potential chemical reactivity, bio-reactivity (in vitro screening), receptor-binding Fig. 1 . Components of the TT21C approach: the elements that were put together to work towards a safety assessment decision in the prototype-pathway case-study (see text for details).
potential, and signature profiling such as connectivity-mapping for molecular initiating event (MIE) alerts that can lead to a decision on the potential impact on pathways of relevance to the risk assessment (Gutsell and Russell, 2013) . A more thorough consideration of the tools and approaches that we envisage should be employed to make decisions on the significant toxicity pathways, which require subsequent investigation, will appear elsewhere. In this case study we have assumed those initial investigations have been performed and the key pathway of concern selected. Such pathways can be explored in the necessary detail by characterizing the dose-dependent effects of the chemical agent in human cells in culture; exploiting the data-dense outputs of a combination of high throughput methodologies, including high-content imaging, flow cytometry and transcriptomics. The key to collecting valuable data from in vitro assays is the use of carefully designed, fit-for-purpose assays in relevant cell-types with appropriate readouts over different degrees of perturbation. These multiple data streams then feed development of computational systems biology pathway (CSBP) models that quantitatively describe the interplay between key pathway elements and to, importantly, predict chemical concentrations that may be sub-threshold to adaption (region of homeostasis), within the adaptive response, or responsible for an adverse response within the defined protection goals. By combining these concentration predictions with improved understanding of the free-concentration of the chemical agent in the in vitro systems and more accurate estimations of the systemic and/or organ exposure to that agent using physiologically based biokinetics (PBBK), one can derive in vitro to in vivo (human exposure) extrapolations. The resulting risk assessment would then predict levels of human systemic exposure below which significant, adverse pathway perturbations are not predicted to occur, rather than on extrapolations from high-dose apical end-points in animals (Bhattacharya et al., 2011; Boekelheide and Andersen, 2010) .
Whilst these components of a pathways-based risk assessment have been widely discussed, to date no worked examples of the entire risk assessment process exist. In order to begin to test the above process, we have taken the approach of examining a prototype toxicity pathway (DNA damage responses mediated by the p53 network) and constructing a strategy for the development of a pathway based risk assessment for a specific chemical in a case study mode. This contribution represents a 'work-in-progress' and is meant to both highlight concepts that are well-developed and identify aspects of the overall process which require additional development. The goals of this case study risk assessment are to:
-Establish whether it is feasible to move towards safety decisions based on perturbation of human toxicity pathways. -Inform the process of developing future toxicity pathway approaches. -Help in the understanding of how toxicity pathways could ultimately be used to make safety decisions.
To guide our understanding of what a pathways-based risk assessment could look like in practice, we chose to work on a case study with a defined human exposure and to bring a multidisciplinary team of chemists, biologists, modellers and risk assessors to work together towards a safety assessment on the case-study chemical. The hypothetical case study chosen was to estimate if a proposed use of the flavonoid quercetin (QUE) in a body lotion at 0.5% would cause significant, adverse perturbation in DNA damage/p53 pathway responses if used by a consumer. QUE was selected because it is a consistently positive responder in some in vitro genotoxicity tests (e.g. Carver et al., 1983) , albeit with potential protective effects (Obinaju and Martin, 2010) , but is considered not to be a carcinogen based on the lack of evidence of in vivo genotoxic/carcinogenic properties (Harwood et al., 2007; Utesch et al., 2008) . The current weight of evidence for the human safety of QUE comes largely from lifetime exposure studies in rodents (Harwood et al., 2007) . Our goal was to see if the in vitro dose response for QUE could be sufficiently understood to construct a risk assessment for this chemical without recourse to rodent carcinogenicity study data. This paper describes the current progress in an ongoing research effort aimed at providing a proof-of-concept in vitro-only safety assessment for a consumer use product.
Prototype pathway selection
We selected the p53 DNA damage response network as a prototype cell-signalling pathway as it becomes activated in response to a myriad of stressors, including but not limited to DNA damage, and functions in multiple ways to conserve stability and prevent genome mutation. Levels of DNA-damage that exceed repair capacities will produce adverse consequences, including mutation, cancer and general cytotoxicity. There were several reasons for selecting this pathway as an initial prototype over other stress pathway responses. First, there is already a long history of using in vitro assays in cancer (hazard) safety assessment, e.g., use of mutagenicity tests in bacteria and human cells to predict possible adverse effects in humans. Second, mutations in the p53 gene are strongly associated with human cancer (Hollstein et al., 1991) , so changes in this pathway are relevant in the development of human disease, i.e. part of the adverse outcome pathway (AOP). Lastly, although commonly used in hazard identification, tests for DNA damage are underutilized risk assessment tools. This last reason suggests an opportunity to expand the application of DNA-damage assays for more quantitative safety assessments. Going forward, at least in the EU, risk assessments for genotoxicity assay-positive novel cosmetic ingredients will not have access to new in vivo mutagenicity or lifetime cancer studies. Tools for in vitro assessments need to be available to aid the transition to safety assessments for DNAreactive compounds.
Prototype chemical selection
QUE is a naturally occurring flavanol present in green tea and a variety of berries, fruits and vegetables. In the United States, the average daily dietary intake of QUE is about 25 mg (National Toxicological Program, 1991) . QUE is available as an herbal supplement due to purported antioxidant (Das and Vinayak, 2012) , anti-inflammatory (Gonzalez-Segovia et al., 2008) , chemotherapeutic and chemoprotective effects (Jagtap et al., 2009 ). There is interest in using the flavonoids such as QUE in the prevention and treatment of cancer. In animal studies, QUE retards tumour growth and inhibits the effects of known carcinogens, i.e., arsenic, azoxymethane, etc. (Turner et al., 2009 ). However, QUE also increases point mutations in mouse lymphoma L5178Y cells in vitro (Carver et al., 1983) and micronuclei in MCF-7 cells (Obinaju and Martin, 2010) . The apparent disparity between in vitro and in vivo results makes these chemicals interesting targets for development of in vitro assays to better define their mechanisms (and the dose-response) of DNA damage and subsequent initiation of cellular responses that may prevent permanent mutation in vivo. Indeed, such food-derived flavonoids exemplify the need for more detailed pathways-based approaches for understanding and risk assessing the otherwise misleading 'flag' of in vitro genotoxicity, without recourse to animal tests.
Components of the approach

Exposure and consumer use assessment
An estimation of human exposure should be one of the first steps in modern toxicological risk assessment. An understanding of the route and extent of chemical exposure to consumers informs the level of concern and the data needed to complete a robust risk assessment. When human exposure is very low, techniques such as exposure-based waiving are now more readily accepted by scientists and regulators than ever before (recent EFSA and SCCS opinions: EFSA, 2012; European Commission's Scientific Committee on Consumer Safety, 2012). This change is being driven by a broadening of the scope of application of the threshold of toxicological concern (TTC) concept, both in terms of chemical applicability and health effects (Carthew et al., 2009) .
Where human exposure is higher and toxicology data are required to complete a risk assessment, the dose or concentration selection is critically important. The value of generating toxicology data at unrealistically high doses or concentrations has been questioned for some time (NRC, 2007; Krewski et al., 2010) . Furthermore, use of high doses in biological tests in a small number of subjects necessitates the use of large 'assessment' or 'uncertainty factors' to provide reassurance that risk assessments are protective of large and heterogeneous human populations. Hence, one benefit of moving towards a more mechanistic basis for toxicological risk assessment could be increased understanding of how population variability relates to the relative sensitivity of the test system(s). The question risk assessors should be trying to answer is 'what are the risks associated with normal or reasonably foreseeable use of this chemical?' Put in a consumer product context, this translates to the question, 'can chemical x be safely used at y% in product z?' Phrasing the question in this way takes G Model TOX-51352; No. of Pages 10 emphasis away from demonstrating the hazards that could be associated with high dose exposure to a chemical, and towards providing reassurance that realistic or foreseeable chemical exposures will not significantly perturb cellular signalling pathways and the end use of the product will cause no harm to consumers. Thus, whilst an understanding of actual human exposures has increased in importance in toxicological safety assessment in recent years, we envisage it will become central to future approaches to risk assessment.
The product type selected for our hypothetical risk assessment was body lotion. For this product type the dermal route of exposure is considered for the systemic toxicity safety evaluation. The typical method of calculating the human systemic exposure dose to an ingredient in a skin lotion considers the level of incorporation of the ingredient, a reasonable worst-case assumption of consumer use of the product (how much of the product is applied and how frequently), physiological data such as body weight and a measurement or estimation of the extent of skin penetration (EU Scientific Committee on Consumer Safety, 2012). This information is used to calculate the body burden to the ingredient in terms of mg ingredient applied/kg bodyweight/day. This is a useful metric when comparing body burden between humans and experimental animals but is of limited use when performing in vitro to in vivo extrapolation, where a more thorough understanding of internal (tissue and plasma) exposure is required. Nonetheless, either estimation of consumer exposure requires fundamental information on consumer use of the product in question. We used information from a study of consumer use practices in North America (Loretz et al., 2005) , selecting a value of 15 g body lotion/person/day, which was between the 90th and 95th percentile amount applied per day in that study. Evaluation of data modelled for the European population provided reassurance that this figure is a reasonable worst-case that would cover the majority of users of this product type, and therefore is suitable to use in a risk assessment. A consumer using 15 g of a body lotion containing 0.5% QUE would therefore be applying approximately 75 mg QUE to their skin per day (15 × 0.005 × 1000).
This information was used in a physiologically based biokinetic (PBBK) model to estimate in vivo QUE concentrations. PBBK models predict free concentrations in plasma and tissues using in vitro data on absorption, distribution, metabolism and excretion (ADME) in the body (NRC, 2007; Blaauboer, 2010) . Other processes may affect the free concentration in vitro, including evaporation, binding to apparatus, binding to proteins in media, and metabolism within the cells.
For the QUE hypothetical case study in a body lotion, the first step from exposure to tissue concentrations is absorption into and transport through the skin. Because existing studies on skin absorption did not use body lotion as the vehicle, it was not possible to predict and compensate for the effects of vehicle on absorption rates. Hence, we performed an in vitro skin penetration study with 14 C-radiolabelled QUE formulated in body lotion, using the time course skin penetration method (Pendlington et al., 2008) in order to assess the biokinetics of QUE in skin tissues as well as the absorption rate. Using previously described analysis methods (Davies et al., 2011) we developed an empirical biokinetic skin model from the data to predict the skin concentrations and systemic absorption rate at steadystate following repeated daily exposures (Figures S1 and S2; Table S1 in Supplemental Materials). Concentrations in plasma and other tissues were estimated using a PBBK model for QUE developed in GastroPlus TM (http://www.simulations-plus.com/). The steady-state concentration of chemical in plasma was modelled as arising from an intravenous infusion at the rate of skin absorption ( Figure S3 and Table S2 in Supplemental Materials).
2.2. High-content information in vitro assays in human cells and models and dose-response assessments 2.2.1. High throughput assay selection Cellular assays were developed for several endpoints in the DNA-damage response pathway in a human cell line derived from a biopsy of a fibrosarcoma from a 35 year old male Caucasian (HT1080) . The HT1080 cell line was chosen because it is a human cell line expressing normal p53 and it has been used in the published literature to study p53 signalling (Rasheed et al., 1974; Sun et al., 2013) . This cell line is also adherent, which allows better imaging for studies of localization of key proteins in the p53 response pathway and micronuclei formation (Paull et al., 2000) . Further, this cell line was found to be genetically stable (Table S5 in Supplemental Materials). While the use of a cancer line clearly presents some challenges in interpreting DNA damage response data, the use of a cell line has an important advantage over primary cells: the cells can be used for many passages. Thus, cells may be used for many assays without the added complications of donor-donor differences, senescence, etc. To ensure conclusions from the HT1080 assays were not cell-line specific, many of the assays were also run in other human cell lines (HCT 116, AHH-1) which gave broadly similar results which will be presented elsewhere (Clewell et al., Submitted to Tox. Sci. 2014) .
Using the terminology of the AOP conceptual framework (OECD, 2011) the measure of adversity was micronuclei (MN) formation in this case. MN are formed when fragments of a chromosome, or entire chromosomes, are not incorporated into the daughter nuclei during mitosis. Exposure to DNA damaging compounds can cause induction of MN due to increased incidence of unrepaired double strand breaks. The micronucleus assay, which has been standardized under the OECD guidelines (OECD, 2010) , is a widely used screen for genotoxic compounds. For the purposes of our case study, the MN assay served as a measure of permanent chromosomal damage, which we considered an adverse outcome of chemical exposure. MN were evaluated with the automated Cellomics TM micronucleus assay, enabling high-throughput automated scoring of individual cells using a multiwell format .
Within the context of the risk assessment for DNA damage, a prerequisite is the mechanistic understanding of how the cell recognizes and responds to different forms of DNA damage, which may subsequently affect the mutation rate. p53 has been shown to be a key control mechanism for cell cycle arrest and apoptosis, and is also required for aspects of nucleotide excision repair (Bhana & Lloyd, 2008) . In a series of publications, Lahav and colleagues, amongst others (Lahav et al., 2004; Batchelor et al., 2011) described a core network for the p53 regulator illustrating how the structure and subsequent signalling dynamics determine cellular fate in response to double strand DNA breaks caused by irradiation. We used this work to define core modulators of the central circuitry of this pathway (Fig. 2 ). High throughput assays were then developed to measure these modulators over dose and time in order to characterize the p53 response network and identify dosedependent transitions in the DNA damage pathway following QUE exposure. These pathway biomarkers were examined along with the micronuclei.
The pathway biomarkers included input stressors such as reactive oxygen species (ROS), and p-H2AX (as an indirect marker for double strand DNA breaks). The measured upstream kinases were p-ATM, p-ATR, and p-Chk2. Other endpoints were direct p53 responses such as total p53 protein levels and post-translational modifications of p53 (p-p53(ser 15), p53(ser46)), and modulators of p53 including MDM2 and Wip1, which modify the dynamics of the p53 response in combination with output regulators. Additionally, the cell state biomarkers measured apoptosis, cell cycle arrest, cell death and MN. 
Dose-response assessments
Eighteen point dose response curves were generated from 0.06 to 100 M for QUE using high throughput flow cytometry and imaging techniques to determine doses that resulted in significant perturbation. Data on the various biomarkers for p53 pathway activation were then aligned and anchored to DNA damage and micronuclei formation (Clewell et al., Submitted to Tox. Sci. 2014; Sun et al., 2013) . Relative sensitivity of the various biomarkers was analyzed in three ways: LOEL (lowest dose causing a statistically significant change from control), benchmark dose (BMD), and 95% lower confidence interval for the BMD (BMDL). The LOELs, BMDs and BMDLs were then compared across protein and cell fate biomarkers (Table 1) .
Determining points of departure based on media chemical concentration
Initial determination of NOELs and BMDs were performed using nominal media concentration. However, just as metabolism and disposition determine tissue dose in vivo, a variety of kinetic process may alter cellular exposure in vitro. In an effort to more accurately characterize cellular QUE exposure, we performed a series of experiments designed to determine the stability of QUE in our cell cultures.
We took QUE in DMSO at 100 mg/ml and diluted this stock solution with DMSO and aqueous culture medium. Measurements of total (dissolved) QUE concentration in media immediately after application recovered approximately 50% of nominal. Measurements of total QUE concentrations at later time points showed that QUE was unstable in the culture media. Its stability varied depending on media composition, i.e. QUE was stable in pure water over the 4 h dosing time of the micronucleus assay. However, it was unstable in media without foetal calf serum (FCS). The rate of QUE degradation was lower in culture medium containing 5% FCS, but still rapid enough to leave virtually none of the QUE detectable at the end of the exposure period. These results exemplify the challenge of choosing the correct dose metric for in vitro assays to facilitate quantitative in vitro to in vivo extrapolation, a subject which has recently been reviewed by Groothuis et al. (2013) . In cases where concentrations of the test chemical in the test system are not constant due to effects such as degradation, metabolism or evaporation, alternative measures of NOELs, based on time course curves of QUE in the culture system can be generated such as AUC (area under curve) or TWA (time weighted average). However, comparison to the corresponding in vivo measures is not straightforward, e.g. what timescale of dosing in vivo should be considered, and why should it relate to the timescale of the in vitro assay that is probably defined by methodological requirements? The most robust approach would be to use the complete concentration-time profiles from both in vitro and in vivo, and integrate these TK outputs with a TD model to predict and compare the responses between the two scenarios, allowing extrapolation from short term in vitro cell experiments to chronic exposure scenarios in vivo.
One further aspect associated with the observed degradation of QUE to be considered is the products of this reaction. Investigations into the degradation products of QUE in the treatment medium tentatively identified a number of chemicals which in previous studies on QUE degradation have been associated with an oxidative reaction mechanism. These compounds or other intermediate reaction products can be structurally similar to QUE and may have DNA-damaging properties in their own right.
Dose-response evaluations
Our initial hypothesis examined the idea that maintenance of genome integrity at exposures just below the threshold for micronuclei would result from p53 controlled cell cycle arrest and induction of DNA repair proteins. For the mutagenic alkylating agent EMS and MNU respectively, Zair et al. (2011) and Thomas et al. (2013) suggested that saturation of repair processes resulted in accumulation of damage at higher treatment levels. In contrast, we found that induction of ROS and ␥H2AX, and the other biomarkers of p53 activation, all occurred at similar doses to those required for MN formation (20-30 M). The exceptions were apoptosis and cell cycle arrest, which occurred at doses higher (∼60 M) than the LOEL for micronucleus formation.
Several possibilities exist that could explain this disparity: chemical interactions within the in vitro environment may limit the free concentration at low doses; low dose mechanisms may not require p53; the biomarkers examined may not control low dose responses; or, importantly, our fundamental hypothesis may be wrong. To address these specific procedural issues we expanded our studies.
14 C-Quercetin uptake experiments measured the cellularassociated QUE at doses below the reported point of departure. From 0.5 M through 10 M there was a proportional dosedependent increase in QUE in HT1080 cells (Table S5 in Supplemental Materials). Parallel experiments with unlabelled QUE confirmed that approximately 30-90% of the radiolabelled material detected associated with the cells at the highest dose was QUE (Table S6 in Supplemental Materials). Considering that degradation of QUE in the culture medium was observed, it has to be assumed that a considerable proportion of the radiolabelled material after four hours of exposure is made up of degradation or metabolic products of QUE. However clearly, free QUE was available below the indicated LOEL for the measured biomarkers of 20 M. We looked for the presence of additional mechanisms for low exposure adaptation at a transcriptional level by conducting whole genome microarrays. Transcriptomic dose-response studies were performed using the Affymetrix Titan gene array platform, which allows simultaneous analysis of 96 samples from as little as 250 ng mRNA. Transcriptomic response was evaluated at 0, 1, 3, 10, 30, and 100 M QUE, a dose range that covers the range of no observed change in MN to maximal response (Clewell et al., Submitted to Tox. Sci. 2014) . The dose at which no statistically significant gene changes were observed (NOEL) was 3 M QUE. These data were also analyzed using BMDExpress (Yang et al., 2007) to determine the BMD for coordinated groups of genes (grouped by gene ontology category). The BMD and BMDL for the most sensitive gene ontology category (development) were 12 and 8 M, respectively (Clewell et al., in preparation) . Interestingly, these data indicate that gene transcription does not occur at lower doses than MN formation. These microarray results raised an intriguing possibility; the point of transcriptional response may only occur at the higher levels of DNA damage resulting in a coordinated transcriptional cascade to enable cell survival. If this were the case, the exposures causing transcriptional activation are already in what might be termed the 'adverse' category (Fig. 3) .
Because gene transcription occurs at doses associated with MN response, we are left with the question of how cells would respond to damage in dose regions below those activating gene transcriptions. Many non-transcriptional responses occur after treatment of cells with DNA-damaging agents. An early (30 min) transcription independent p53 dependent apoptotic response occurs in some organs of ␥-irradiated mice (Erster et al., 2004) . UVB induced DNA damage results in the differential regulation of mRNA translation and increased translational efficiency of NER genes (Powley et al., 2009) . In assessing cellular stress, Warringer et al. (2010) suggested three phases of response: the most immediate response occurs via protein stabilization and modification, followed by translational reprogramming and finally by a slower, more, energy costly transcriptional response. Rapid responses to DNA damage are highly dynamic (Polo and Jackson, 2011) with rapid recruitment and dissociation of factors for single strand and double strand DNA breaks.
Similarly modelling of NER (Sokhansanj, 2005) showed responses within two hours. Neumaier et al. (2012) found that resolution of repair foci as measured by p53BP is dose dependent with more efficient formation of repair foci at lower levels of damage. Initial time dependant studies on the dynamics of the response indicated modifications to the ser15 site of p53 at low exposures in our studies. At higher doses we observed a clear increase of this activation up to 6-8 h following QUE treatment, which is maintained through to 24 h; at lower doses the response looks transient, peaking at 4 h and returning to baseline. We are currently exploring this together with other modifications to p53 in more detail to define their possible role in the low dose adaptive response. Further, we are examining the formation of repair foci (repair foci localized at sites of DNA damage) in an effort to quantify non-transcriptional response to DNA damage at doses below those required to induce MN formation (see Section 3 and Fig. 3 ).
Computational models of the circuitry of relevant pathway
The NAS TT21C report defined toxicity pathways as cellular response pathways that result in an adverse health effect following sufficient perturbation (NRC, 2007; Krewski et al., 2010) . Informatics approaches using databases such as the Comparative Toxicogenomics Database, KEGG, MetaCore and IPA, in combination with 'omics' data can identify toxicity pathways. The output of using informatics is a list of prioritized pathways/biological processes but with very little understanding of the dynamics of the pathway. Computational systems biology pathway (CSBP) models have promise in predicting pathway dynamics over wide dose ranges, informing extrapolations to low levels of exposure, and indicating how adverse events perturb the pathway and the nature of its basal (normal) dynamics. Additionally, an overarching purpose in using CSBP models is to provide deep, mechanistic understanding of the experimental data in order to support risk assessment/safety decisions.
Biological systems are inherently non-linear with respect to dose response and pathways are populated with a variety of recurring motifs that serve, through negative feedback, to maintain systems against perturbations and to move systems from one state to another (Alon, 2007; Zhang et al., 2013) . There are homeostatic regions where the cell responds to maintain normal function over some region of perturbation. The extent of this adaptive region in the dose response curve can serve to determine a potential NOAEL. Further perturbation of the pathway, saturating the adaptive machinery, plays the key role in eliciting adverse responses. Determining the so-called 'tipping point' between adaptive and adverse regions of response or 'point of departure' (POD) is an essential component for safety assessment decisions. However, rather than relying simply on POD, CSBP models can help understand pathway dynamics, thereby reducing uncertainty by rooting the risk assessment in deeper biological understanding of the structure and function of the pathway.
A body of work over the past 10 or so years has documented the dynamics of the p53-mdm2 DNA-damage response pathway in response to double/single strand breaks (DSB/SSB) (Batchelor et al., 2011) . DSB induced by gamma radiation activate the ATM signalling pathway causing oscillations of p53 via negative feedback loops within the circuit. A different p53 dynamic is observed in response to UV-mediated DNA damage and has a different signalling network with more persistent activation of p53 rather than the DSB-oscillation (Batchelor et al., 2011) .
Prior to construction of a computational model, several questions needed to be addressed e.g. how does QUE cause DNA damage? What is the sensor kinase(s) for QUE and what are the dynamics of p53 activation? Can we link/anchor the model to an adverse response, i.e. the formation of micronuclei? The mechanism of action for QUE is not fully understood, however it has biphasic dose responses (∼1-40 M: antioxidant responses; 40-100 M: pro-oxidant responses) on cells depending on its concentration (Vargas and Burd, 2010) . QUE forms DNA adducts (van der Woude et al., 2005) and DNA damage by single-and doublestrand breaks through reactive oxygen species (ROS) (Min and Ebeler, 2009; Ye et al., 2004) in a dose dependent manner, and is a topoisomerase II inhibitor at higher doses (30-50 M; Cantero et al., 2006) . The sensor kinase for QUE is also unclear, although QUE may cause phosphorylation of p53 via other kinases such as p38 and PLK3 (polo-like kinase 3) rather than ATM (Ye et al., 2004) .
Working with a pragmatic ordinary differential equation model, modified from Batchelor et al., of p53 with three different kinases: ATM, ATR and p38 (simplified in Fig. 2 ) to capture the potential mechanism of action for QUE and investigate likely the crosstalk between kinases ( Figure S4 and Table S7 in Supplemental Materials). In this model, micronuclei arise from ROS, SSB or DSB with varying efficiency. Activated p53 repairs the SSBs and DSBs from QUE exposures and the current model predicts a switch-like behaviour in micronuclei formation ( Figure S5 in Supplemental Materials), i.e. the level of micronuclei formed increases abruptly once the QUE levels reach a certain threshold. This switch-like behaviour could arise from sequential kinase-mediated post-translational alterations in p53. The pathway modelling is a work-in-progress drawing on the 10-year efforts of Alon, Lahav, Batchelor and others looking at high levels of damage, and more current efforts to assess dose response across a wider range of doses (Li et al., 2013; Clewell et al., Submitted to Tox. Sci. 2014) . Overall, at this point in our case study, the transcriptional point-of-departure appears to represent a transition from the posttranslational modification-mediated adaptive region of response, to one of adversity (Fig. 3) . The CSBP model contribution will be to show the overall dose response in the adaptive region by accounting for background repair and dynamic control of pre-existing DNA-repair capacities. The detailed output of the CSBP will appear in subsequent publications.
In vitro to in vivo extrapolation based on biokinetic models
In vitro to in vivo extrapolation (IVIVE) infers the probability of an in vivo adverse outcome at relevant human exposures from the level of pathway perturbation observed in vitro (Blaauboer, 2010) . The ideal in vitro measure is concentration of chemical at the site of action that initiates pathway perturbations, e.g. at sites of potential DNA damage for directly genotoxic chemicals. However, there may be uncertainty about the site of action, and even when known, it may be difficult to measure the concentration at specific sites. A more practical starting point is a measure of free concentration in solution, in which case, IVIVE compares free concentrations in plasma or tissues in vivo to the free concentration in media in vitro. It was therefore our intention to compare free QUE concentration in the in vitro system with the predicted free QUE concentration in plasma and tissues following consumer exposure. Since a robust method to determine free QUE concentration in our in vitro systems is still being developed, this first-tier risk assessment compares total (applied) QUE concentration in the in vitro systems with predicted total QUE concentration in plasma and tissues. The purpose of this comparing the information from the PBPK model described in Section 1 with the points of departure in Table 1 is to determine the likelihood that consumer use of the hypothetical product would lead to a systemic perturbation in the p53 pathway, leading to an adverse event. Performing this extrapolation requires certain assumptions both in the exposure and the effects data. For example, in the absence of a robust method for measuring or predicting free QUE concentrations in the in vitro system, an assumption has been made that the extent of free QUE is similar between an in vivo system and an in vitro system of the same total QUE concentrations. This is unlikely to be the case given the different characteristics of these systems (presence of plastic in the in vitro system, differing protein levels between the in vitro and in vivo systems). This is clearly an area of the risk assessment that requires refinement.
Risk assessment based on exposures below the levels of significant pathway perturbations
The total plasma QUE concentration following consumer use of the hypothetical product was predicted to be 9.1 nM (C max at steady state), with little or no partitioning into the tissues. In this example of skin exposure, the maximum concentrations (C max ) in viable skin and plasma are equivalent to the steady state concentrations achieved in each compartment, and these values were considered in relation to the concentration-response profiles from the in vitro assays. The area-under-the-curve of concentration versus time (AUC) is another widely used biokinetic metric, but not appropriate to use in this context because it is not clear over what time-scale the AUC should be calculated in vivo from the biokinetic model; and in an in vitro assay, the time-scale is determined by the method used, therefore the in vitro AUC would be determined by the study design and not the toxicological response. In scenarios where the concentrations (either in vivo or in vitro) vary substantially over time, it may be appropriate to compare the average concentrations over time (AUC divided by time-scale) rather than the C max values. However, the steady state C max plasma concentration was significantly lower than the dose required to perturb the elements of the pathway that we evaluated (Table 1) . Furthermore, the plasma concentration was much lower than the dose required to cause the adverse event of micronucleus formation (BMDL = 1 M). We would therefore predict that there is a low probability that the reasonable use of the hypothetical product would result in a systemic perturbation of the p53 pathway, and would not be associated with an increased risk of micronuclei formation. From this the biokinetic models, the application of body lotion led to concentrations of free QUE at the site of application in skin of approximately 5000 M, a value more than six orders of magnitude greater than the expected concentration in plasma or other tissues ( Figure S3 and Table S3 in Supplemental Materials). Therefore, an important area we need to resolve in approaching the safety assessment using the data we have generated is how to approach the high predicted free concentration of QUE in the skin. This is a different question to our objective of attempting a pathways-based systemic evaluation, and could be tackled in a variety of ways, e.g. using 3D skin models to refine the hazard characterization. A more fundamental question in the development of an in vitro AOP-driven approach to safety evaluation, especially in cases where systemic exposure is closer to the levels that cause pathway perturbation, is how the results of assays and models will be integrated to arrive at a more quantitative safety assessment which can describe the underlying biology and is more explicit about the sources of uncertainty.
Recently, Judson et al. (2011) integrated results from several in vitro assays associated with biological/toxicity pathways into a systems-level model to estimate probability distributions for a so-called Biological Pathway Altering Concentration (BPAC). Population biokinetic modelling estimates the external dose through the relevant route of exposure that would lead to the internal BPAC. Merging the biodynamics and biokinetics yields a probability distribution of the dose at which the chemical would significantly perturb the biological/toxicity pathway. Calculated means and confidence intervals from this distribution are used to set the chemical-specific Biological Pathway Altering Dose (BPAD) which is analogous to a mechanistically linked no/low effect level (N/LOEL) and the lower dose boundary of the confidence interval. Some challenges with the BPAD concept are in the types of assays employed, i.e., focus on available assays examining one or another subset of properties of a toxicity pathway and minimal attention on pathway dynamics. In addition, the empirical analysis of dose response is a limitation in dealing with DNA-damaging compounds where extrapolations usually follow linear extrapolation to zero-dose.
While in early stages of development, the biokinetic and CSBP models described in this contribution should provide better definition of low dose outcomes and strengthen evidence for regions of DNA-damage where there should be no net increase in adverse consequences due to adaptive homeostasis, perfect adaptation and integral control. The Unilever/Hamner case study with p53 pathway responses for QUE and other prototype compounds moves the TT21C concepts to practice with a high visibility pathway.
Discussion and conclusions
Initial efforts in this case study focused on developing exposure estimates, defining key pathway readouts for p53-mediated DNA damage responses, developing high throughput in vitro assays, beginning computational model development of the p53 pathway and utilizing biokinetic models to perform IVIVE. Clearly with QUE we had selected a case study chemical for which an in vitro flag of genotoxicity had already been identified. For a new or datapoor compound, a number of tools will be needed, combining both chemical reactivity characterization (including in silico) and high throughput (HTS) bioassays to identify significant pathway perturbation potential (including some well established in vitro genotoxicity measures). Furthermore, we have only focussed on the p53 network as a central response to DNA damage. Other pathways may be more or additionally relevant for other chemicals; these will have to be determined on a case-by-case basis but an exposure-led and informed approach will dictate the relevant pathway(s), rather than the application of an indiscriminate list of pathways that must all be explored. The preliminary analyses have, however, led us to several important conclusions that will influence our future work, including that an understanding of in vitro kinetics is critically important to the interpretation of in vitro assays. Also importantly we have found that the p53 transcriptional response does not prevent MN induction at low doses. In other words, MN induction occurs at doses equal to, or lower than, doses required to activate p53-mediated gene transcription. This observation is important because it indicates that any protective effect of p53 is likely due to p53's activity as a recruitment factor for repair proteins at the site of DNA damage. In order to better define the tipping point between adaptive (i.e. homeostasis) and adverse responses, we have decided to focus our next research on non-transcriptional responses to DNA damage. Homeostasis likely requires perfect adaptation of both rapidly acting pathways (posttranslational modification e.g. phosphorylation) and slower (energy demanding) acting pathways (i.e. transcriptional changes to gene expression). This theory suggests that small perturbations to the pathway would result in non-transcriptional activation of repair centres in response to low levels of DNA damage. The formation of repair centres and post translational modification of p53 could provide mechanistic understanding of threshold behaviours at low doses, explaining how mutation rates can be kept at basal levels with increasing chemical treatment. Increases in dose may, at some point, cause the pathway to move into transcriptional control. This switch to transcription (i.e. tipping point between adaptive and adverse responses) could be as a result of depletion of p53 reserves or other post-translational modification and increases in gene expression of key biological processes could be measured and used as markers for adversity. An attractive aspect of the focus on p53 is the ease of extending the case study to other forms of DNA-damage, e.g., double strand breaking chemicals, alkylating compounds and UV-light.
Since the NAS report, rapid progress has occurred in the US with HTS methods applied by ToxCast (http://www. epa.gov/ncct/toxcast/) to several thousand compounds. This work supports prioritization for further testing, as with the new EPA Endocrine Disrupter Screening Program for the 21st Century, or for creating provisional risk assessments (Judson et al., 2011) by combining the HTS methods with so-called high throughput exposure assessments (Wetmore et al., 2012) . With movement towards reauthorization of the toxic substances control act (TSCA) in the US, some of these cell-based methods for HT-risk assessment may move towards acceptance and implementation in specific legislation. These approaches could be quickly embraced for compounds with little biological activity in HTS tests and with low level human exposures. Initial acceptance of the tools for a subset of commercial compounds would make the procedures more palatable and begin steps necessary for more general acceptance in regulation of environmental chemicals. With continuing progress in the ToxCast programme and legislative pressure, these tools could become commonplace in the regulatory environment within five years. Other challenges will persist with more active compounds, for those with higher exposure potential and for those used more extensively in consumer products and food. Nevertheless, as these cell-based tools become commonplace, the toxicology and regulatory communities will see them used and will gain increasing familiarity and comfort. Early-on acceptance will likely come from young rather than entrenched practitioners.
With other compounds possessing greater biological activity and higher consumer exposures, the path to implementation will likely come from successful case studies, as discussed here. Case studies show the application of a new understanding of toxicity pathways directly for human health risk assessment and do it quickly -within two to three years. Progress in developing a wider group of case studies requires careful selection of prototype compounds and prototype pathways. At Unilever and at The Hamner Institutes, a group of receptor-mediated and stressresponse mediating pathways are being explored. Success with these case studies requires refinement of assay design, integrative genomics/bioinformatics tools, computational modelling, and pharmacokinetics to move results directly to human health risk/safety assessments. The case studies offer many advantages. First, they focus on developing the generic tools for using cellbased methods and computational modelling. Second, they endorse "learning by doing". Many key issues will become apparent by moving ahead with examples rather than worrying over how to make wholesale changes in the regulatory environment. In the work on our p53-DNA damage pathway, we had to move from our original emphasis on transcriptional regulation of the stress pathway to consider the generic role of rapid, post-translational modification (PTM) for the control of lower levels of chemically induced DNA damage and the role of PTM in other stress pathways.
Adverse outcome pathways (AOPs) now emphasize linkages of molecular initiating events, toxicity pathways and downstream consequences for toxicity. AOPs show the causal linkage for pathway perturbation to conventional in-life responses, providing a basis for using cell-based assays with well-defined in vitro models for safety assessment. Successful case studies get ahead of the current discussions on design of AOPs and could stand ready to show how the pathway projects link into an AOP-safety assessment framework. As noted for regulatory acceptance in the US, several well-designed case studies that mature as the AOP thinking becomes more widespread, could catalyze regulatory acceptance of these new tools over the next two to five years. Success with one or two pathways will also encourage investment of resources and talent in examining other pathways.
It is some years now since the National Research Council report on Toxicity Testing for the 21st Century (TT21C). Many aspects of the framework for pathways-based risk assessments have been described elsewhere but we consider that this paper represents a significant stepping-stone towards practical implementation of TT21C, and will pave the way for other new risk assessments based on other toxicity pathways and their dose-dependent perturbations. We have hopefully highlighted many of the current challenges and subsequent papers will refine and improve upon that which we have presented here, however, the path via 'pathways' is firmly begun, www.TT21C.org.
